Recomendaciones generales para la vacunación

Please note: An erratum has been published for this issue. To view the erratum, please click here.

Morbidity and Mortality Weekly Report
Recommendations and Reports / Vol. 60 / No. 2

January 28, 2011

General Recommendations on Immunization
Recommendations of the Advisory Committee
on Immunization Practices (ACIP)

Continuing Education Examination available athttp://www.cdc.gov/mmwr/cme/conted.html

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

CONTENTS

Disclosure of Relationship

Introduction ............................................................................................................ 3Methods.................................................................................................................... 4
Timing and Spacing of Immunobiologics .................................................... 4
Contraindications and Precautions.............................................................. 10
Preventing and Managing Adverse Reactions......................................... 11
Vaccine Administration .................................................................................... 13Storage and Handling of Immunobiologics ............................................. 17
Altered Immunocompetence ........................................................................ 19
Special Situations ............................................................................................... 23
Vaccination Records.......................................................................................... 30
Vaccination Programs ....................................................................................... 31
Vaccine Information Sources ......................................................................... 34
Acknowledgments ............................................................................................. 35References............................................................................................................. 52
Abbreviations ...................................................................................................... 59
Glossary.................................................................................................................. 60

CDC, our planners, and our content experts wish to disclose thatthey have no financial
interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. This report will not include
any discussion of the unlabeled use of a product or a product under investigational
use with the exception of the following situations:
1. The nonsimultaneous administration of yellow fever (YF) vaccine andinactivated
vaccines.
2. Simultaneous administration of an inactivated and live vaccine (e.g., pneumococcal
polysaccharide vaccine [PPSV] and zoster [Zos] vaccine).
3. Interchangeability of combination vaccines and single-component vaccines (e.g.,
using single-component Haemophilus influenzae type b [Hib], diphtheria and
tetanus toxoids and acellular pertussis (DTaP), and inactivatedpoliovirus [IPV]
for later doses in series, after a series has begun with DTaP-IPV/Hib).
4. Interchangeability of brands of combination vaccines and single-component
vaccines (e.g., using DTaP-IPV/Hib and single-component hepatitis B [Hep B]
vaccine for later doses in series that might have previously included DTaP-IPVHepB and Hib).
5. Rotarix and RotaTeq need not be repeated if an infant spits upor regurgitates a dose.
6. Contact allergy to latex is neither a contraindication nor a precaution to the use
of quadrivalent meningococcal conjugate vaccine (MCV4) in the absence of an
anaphylactic allergy.
7. No need to repeat a dose of MCV4 vaccine given subcutaneously.
8. Revaccination with MCV4.
9. Appropriate storage and handling for the following vaccines at 35°F–46°F:
• DTaP
•...